ArticleClinical oral investigations2024
Therapeutic potential of farnesoid X receptor agonists for modulating inflammation and periodontal regeneration.
Article in Clinical oral investigations, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesInflammation and osteoclast activity are important in various diseases, including periodontitis and osteoporosis. Farnesoid X receptor (FXR) has been identified as a promising target for modulating these processes. This study delved into the impact of FXR agonists on inflammation and periodontal regeneration using periodontitis models. MATERIAL AND
methodsThe RAW264.7 and gingival fibroblast cells were divided into five groups: control, lipopolysaccharide (LPS), LPS combined with FXR agonist, LPS with si-FXR, and LPS with si-FXR alongside FXR agonist. FXR expression and pro-inflammatory cytokine levels were quantified. Osteoclast activity was evaluated by observing morphological alterations and tartrate-resistant acid phosphatase staining. The rats were used to establish periodontitis models and received varying doses of FXR agonist. Bone health metrics were assessed, and the expressions of runt-related transcription factor 2 (RUNX2), integrin-binding sialoprotein (IBSP), nuclear factor-kappa B (NF-kB), phosphorylated nuclear factor-kappa B (p-NF-kB), toll-like receptor 4 (TLR4), and toll-like receptor 2 (TLR2) were determined.
resultsFXR suppressed the release of pro-inflammatory cytokines in both LPS-stimulated RAW264.7 and gingival fibroblast cells, while curbing osteoclastogenesis. In periodontitis rat models, FXR agonist administration caused notable enhancement in bone density. Moreover, FXR agonist mitigated periodontal inflammation, decreased periodontal index markers and suppressed the expressions of NF-kB, p-NF-kB, TLR4, and TLR2, but upregulated the expressions of RUNX2 and IBSP.
conclusionThe data underscores the potential of FXR agonists in attenuating inflammation and periodontal regeneration, both in vitro and in vivo. This suggests the potential therapeutic application of FXR agonists in conditions marked by inflammation and bone degradation.
Indexed as
Identifiers
39661179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.